Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30results about How to "Definite inhibitory effect" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Fusion protein of tumour new-born blood vessel-specific bonding polypeptide and recombinant human Tum-5, and its preparation method
InactiveCN1800218AAntitumor effect is obviousPrevent proliferationRecombinant DNA-technologyFermentationTumour tissueEscherichia coli
The invention discloses a method for preparing for tumour formingblood vessel peculiarity binding polypeptide and the admixture protein of human-5. The tumour formingblood vessel peculiarity binding polypeptid-CNGRCVSGCAGRC can separately combine with the tumour formingblood vessel endothelium cell surface high effect expressed aminopeptidase N (CD13). It establishes tumour formingblood vessel peculiarity binding polypeptide and the admixture protein of human-5 and obtains the high effect express in bacillus coli. It also discloses a method for preparing for human Tum-5. The Tum-5 is formed by the 54-132 bits amino acid near the N end of the Tumstatin, which is the function structure area of the Tumstatin anti-vascularization.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Method and application for preparing amide and ester compounds by marine bacillus amyloliquefaciens
ActiveCN107418984ADefinite inhibitory effectBiocideMicroorganism based processesSephadexBacillus amyloliquefaciens
A method for preparing 13-docosenamide by fermenting a marine bacillus amyloliquefaciens BMF01 bacterial strain comprises the following steps: fermentation of the BMF01 bacterial strain and preparation of fermentation broth thereof, acid precipitation of the fermented broth of the BMF01 bacterial strain and methanol extraction, silica gel column chromatography of BMF01 bacterial strain fermentation broth methanol extract, Sephadex LH-20 column chromatography, then the absorption peak of MD-4 components appear at 11.5 min, and is identified to be a structure of the compound 13-docosenamide. The invention also relates to a method for preparing ester compounds from marine bacillus amyloliquefaciens BMF01. The method of the invention produces the 13-docosenamide and ester compounds having the application of inhibiting root rot of wheat. For the first time, five kinds of compounds with bacteriostatic action are prepared on the basis of BMF01 strain. The method has the advantages of simple method and high operability.
Owner:HUAIHAI INST OF TECH
Bacteriostatic and antiviral preparation taking kidney bean phytohemagglutinin as major ingredient
ActiveCN108404111ALower pHRestore self-cleaning abilityAntibacterial agentsAntimycoticsPhytohemagglutininsAdditive ingredient
The invention discloses a bacteriostatic and antiviral preparation taking kidney bean phytohemagglutinin as a major ingredient, and belongs to the technical field of medicines. The bacteriostatic andantiviral preparation consists of the following active components according to relative parts by weight: 0.1-1.0 part of the kidney bean phytohemagglutinin, 0.2-2.0 parts of one or two of stachyose and raffinose as well as one or more of the following active components: 0.1-0.5 part of povidone iodine, 0.1-0.3 part of polyhexylene biguanidine and 0.1-0.5 part of chlorhexidine; and in addition, a thickening agent, which is hydroxyethyl cellulose, is required. The bacteriostatic and antiviral preparation provided by the invention is concrete in components, and is capable of achieving quantitative control and guaranteeing the consistency and stability of overall quality; a concrete inhibitory effect can be achieved on bacteria, fungi and viruses; therefore, the bacteriostatic and antiviral preparation is relatively broad in antibacterial and antiviral ranges; and the product (the bacteriostatic and antiviral preparation), which is required to be preserved at low temperature, is long in preservation duration and convenient to use.
Owner:YUNNAN KANGZHOU BIOLOGICAL SCI & TECH
Application of macleyine alkaloid in preparation of medicine for inhibiting P-gp
ActiveCN104248635ADefinite inhibitory effectIncrease lethalityOrganic active ingredientsAntineoplastic agentsMedicineAlkaloid
The invention provides an application of macleyine alkaloid and its pharmaceutically acceptable salt, a salvation object, a polycrystalline object, an enantiomer or racemic mixture salt, a polycrystalline object, an optical isomer, a racemate , corydalis tuber containing macleyine alkaloid and its extract product, corydalis amabilis and its extract product, and macleaya cordata and its extract product in preparation of medicine for inhibiting P-gp. The invention provides an application of macleyine alkaloid and its pharmaceutically acceptable salt, the salvation object, the polycrystalline object, the enantiomer or racemic mixture salt, the polycrystalline object, the optical isomer, the racemate , corydalis tuber containing macleyine alkaloid and its extract product, corydalis amabilis and its extract product, and macleaya cordata and its extract product in preparation of medicine for auxiliary treatment of tumour. The auxiliary treatment of tumour is capable of reversing tumour multidrug resistance relative to high expression of P-gp, and is cooperated for synergizing antitumor drugs.
Owner:TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
Preparation method of healthcare herbal candy containing traditional Chinese medicine components
The invention relates to a preparation method of healthcare herbal candy containing traditional Chinese medicine components. The method comprises the following steps: crushing pumelo peel, olive and chrysanthemum in a traditional Chinese medicine crusher to obtain pumelo peel powder, olive powder and chrysanthemum powder; B) weighing xylitol, maltitol, honey, the pumelo peel powder, the olive powder and the chrysanthemum powder, mixing the pumelo peel powder, the olive powder and the chrysanthemum powder with an 95wt% ethanol solution, adding the weighed xylitol, maltitol and honey into a beaker 1, and adding the powder mixed with the ethanol solution into a beaker 2 for use; C) heating the beaker 1 in an oil bath pot with paraffin oil and stirring at the same time; when the sugaring off terminal arrives, stopping heating, and starting cooling; when the temperature is 110-130 DEG C, adding the mixed powder in the beaker 2, and uniformly stirring to obtain a herbal candy mixture; and when the temperature is 100-120 DEG C, adding mint and uniformly stirring at a lower speed; and D) when the obtained mixture is cooled to 90-110 DEG C, performing injection molding, and cooling the mixture in a refrigerator to obtain the healthcare herbal candy.
Owner:ZHEJIANG UNIV CITY COLLEGE
Use of Asterias rollestoni Bell extract in preparation of antitumor drug
ActiveCN103230417AModerate antitumor activityDefinite inhibitory effectOrganic active ingredientsDigestive systemN-ButanolSolvent
The invention relates to the field of preparation of antitumor drugs and especially relates to a use of Asterias rollestoni Bell extract in preparation of an antitumor drug. The Asterias rollestoni Bell extract is Asterias rollestoni Bell alcohol extract extracted from Asterias rollestoni Bell by a solvent. The solvent is a methanol aqueous solution or an ethanol aqueous solution or a mixed solution of methanol and ethanol. The Asterias rollestoni Bell extract also can be ethyl acetate extract or n-butanol extract of the Asterias rollestoni Bell alcohol extract. An experiment proves that the Asterias rollestoni Bell extract has moderate antitumor activity, and can obviously inhibit mice H22 solid tumor and mice S180 solid tumor, and especially, the ethyl acetate extract of the Asterias rollestoni Bell alcohol extract has obvious inhibition effects. Therefore, the Asterias rollestoni Bell extract can be used for treating cancers and especially for liver cancer.
Owner:SOUTH CHINA SEA INST OF OCEANOLOGY - CHINESE ACAD OF SCI
Application of polyphyllins in preparation of preparation for treating acnes
InactiveCN107375315AReduce drug resistance and irritationImprove securityAntibacterial agentsOrganic active ingredientsAcne preparationsIrritation
The invention relates to the application of papaya saponin in the preparation of preparations for treating acne, and belongs to the technical field of biomedicine. The present invention uses the self-made saponins of papaya, and observes in vitro experiments with liquid micro-dilution method, and the experiment proves that total saponins of papaya and saponins Ⅰ, Ⅱ, Ⅵ, and Ⅶ are effective against Propionibacterium acnes, Staphylococcus epidermidis and aureus in vitro. Staphylococcus has definite inhibitory effect and is used in the preparation of acne treatment preparations. The beneficial effects of the present invention are: the addition of plant-extracted papaya saponins to acne preparations not only has a definite inhibitory effect on Propionibacterium acnes, Staphylococcus epidermidis and Staphylococcus aureus, but also reduces the drug resistance and Irritation, providing safety of the preparation.
Owner:FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV +1
Preparation method of antibiotic-crosslinked specific demineralized extracellular matrix scaffold
ActiveCN112618797AGood biocompatibilityImprove biological activityTissue regenerationProsthesisCompounding drugsPharmaceutical drug
The invention discloses a preparation method of an antibiotic-crosslinked specific demineralized extracellular matrix scaffold, and belongs to the technical field of bone infection treatment. The invention discloses the preparation method of the antibiotic-crosslinked specific demineralized extracellular matrix scaffold, which comprises the following steps of by using a specific demineralized and decellularized cancellous bone extracellular matrix scaffold (SDECM) as a substrate, carrying out compound drug loading on the substrate and the antibiotics in two forms of electrostatic adsorption and chemical crosslinking, releasing antibiotics in two modes of rapid pH response and accompanying material degradation in an acid environment, and adopting the antibiotics for resisting infection and promoting repair through SDECM, so that the pH-sensitive release drug in the early acidic environment of infection is rapidly sterilized, the drug is slowly released in the middle-late physiological environment for continuous sterilization, the treatment effect of permanent sterilization capability and prevention of infection recurrence is still achieved in the absence of infection, and a new thought and a new tool are provided for antibacterial and repair treatment of bone infection.
Owner:THE AFFILIATED SIR RUN RUN SHAW HOSPITAL OF SCHOOL OF MEDICINE ZHEJIANG UNIV
Application of sanguinarine to restraining growth of staphylococcus lugdunensis
PendingCN110772518AGrowth inhibitionDefinite inhibitory effectAntibacterial agentsOrganic active ingredientsSanguinarineMinimum bactericidal concentration
The invention discloses an application of sanguinarine to restraining growth of staphylococcus lugdunensis. The sanguinarine has better in vitro destroying effects on medicine-resistant staphylococcuslugdunensis and can restrain the growth of the medicine-resistant staphylococcus lugdunensis, the minimum bactericidal concentration is 30 [mu]g / mL, and the minimal inhibitory concentration is 15[mu]g / mL. The invention provides the restraining effects of the sanguinarine on the staphylococcus lugdunensis, and the sanguinarine has high application value in the field of pharmaceuticals and the like.
Owner:SHAANXI UNIV OF SCI & TECH
Application of luteolin in inhibition of growth of multi-drug-resistant providencia rettgeri
ActiveCN110934859AGrowth inhibitionDefinite inhibitory effectAntibacterial agentsOrganic active ingredientsTraditional medicineMedicinal chemistry
The invention discloses application of luteolin in inhibition of growth of multi-drug-resistant providencia rettgeri. According to the invention, because the luteolin has a good in-vitro killing effect on multi-drug-resistant providencia rettgeri, the growth of the multi-drug-resistant providencia rettgeri can be inhibited; and the minimum bactericidal concentration is 30 to 250 microgram / mL and the minimum bacteriostatic concentration is 15 to 125 microgram / mL. The luteolin has an inhibiting effect on the multi-drug-resistant providencia rettgeri and thus has the great application value in the fields of medicines and the like.
Owner:SHAANXI UNIV OF SCI & TECH
Preparation and application of Michael receptor main protease inhibitor targeting novel coronavirus
PendingCN113801187AInhibition of inhibitory effectDefinite inhibitory effectTripeptide ingredientsAntiviralsReceptorVirus inhibitors
The invention relates to a novel double-activation Michael receptor novel coronavirus (SARS-CoV-2) main protease inhibitor. The compounds can effectively inhibit or block the replication of SARS-CoV-2. The invention relates to discovery and application of a compound containing a structural general formula as well as various optical isomers, pharmaceutically active metabolites, pharmaceutically acceptable salts, solvates and prodrugs of the compound in preparation of antiviral drugs for treating novel coronavirus pneumonia (COVID-19). The invention also relates to an intermediate for preparing the compound with the structural general formula and a synthesis method. Each variable in the structure is defined in the specification, and the structural general formula skeleton of the compound is shown in the drawings.
Owner:NANKAI UNIV
Preparation method of a specific demineralized extracellular matrix scaffold of cross-linked antibiotics
ActiveCN112618797BGood biocompatibilityImprove biological activityTissue regenerationProsthesisTherapeutic effectDrug release
The invention discloses a preparation method of a cross-linked antibiotic specific demineralized extracellular matrix scaffold, and belongs to the technical field of bone infection treatment. The invention discloses a method for preparing a specific demineralized extracellular matrix scaffold of cross-linked antibiotics. The specific demineralized and decellularized cancellous bone extracellular matrix scaffold (SDECM) is used as a substrate, and the specific demineralized and decellularized cancellous bone extracellular matrix scaffold (SDECM) is used as a substrate, and the antibiotic is electrostatically adsorbed and chemically adsorbed. Cross-linking two forms of composite drug loading, releasing antibiotics through rapid pH response and accompanying material degradation in an acidic environment, anti-infection through antibiotics and promoting repair through SDECM, so as to achieve pH-sensitive drug release in an acidic environment in the early stage of infection Rapid sterilization, sustained sterilization by slow release of drugs in the mid-late physiological environment, and permanent sterilization ability to prevent infection recurrence in the absence of infection provide new ideas and tools for the antibacterial and repairing treatment of bone infections.
Owner:杭州源囊生物科技有限公司
Application of sanguinarine in inhibiting the growth of multi-drug resistant Enterobacter hallii
ActiveCN110946862BGrowth inhibitionDefinite inhibitory effectAntibacterial agentsOrganic active ingredientsCefotaximeNalidixic acid
The invention discloses the application of sanguinarine in inhibiting the growth of multidrug-resistant Enterobacter hallii. Ceftiaquine, azithromycin and nalidixic acid have good killing effect on multidrug-resistant Enterobacter hallii in vitro, and can inhibit the growth of multidrug-resistant Enterobacter hallii, and the minimum inhibitory concentration is 0.12 mg / mL, the lowest The bactericidal concentration is 0.24 mg / mL, and the invention proposes the inhibitory effect of sanguinarine on multidrug-resistant Enterobacter hallii, which has wide application value in the fields of medicine and the like.
Owner:SHAANXI UNIV OF SCI & TECH
Application of chelerythrine to restraining growth of staphylococcus lugdunensis
PendingCN110946863AGrowth inhibitionDefinite inhibitory effectAntibacterial agentsOrganic active ingredientsBiotechnologyChelirubine
The invention discloses an application of chelerythrine to restraining growth of staphylococcus lugdunensis. The chelerythrine has better in vitro destroying effects on medicine-resistant staphylococcus lugdunensis and can restrain the growth of the medicine-resistant staphylococcus lugdunensis, the minimum bactericidal concentration is 16 [mu]g / mL, and the minimal inhibition concentration is 7.8[mu]g / mL. The invention provides the restraining effects of the chelerythrine on the staphylococcus lugdunensis, and the chelerythrine has wide application value in the field of pharmaceuticals and thelike.
Owner:SHAANXI UNIV OF SCI & TECH
A kind of herpetetrone nano-suspension and its dry powder, preparation method and application
ActiveCN111374944BDefinite inhibitory effectEnhanced inhibitory effectPowder deliveryDigestive systemBiotechnologyOral medicine
The invention discloses a Herpetetrone nano-suspension and its dry powder, preparation method and application, and belongs to the technical field of traditional Chinese medicine oral medicine. The Herpetetrone nanosuspension is prepared by ultrasonic precipitation. The preparation method of the suspension dry powder comprises: preparation of Herpetetrone nano-suspension; preparation of Herpetetrone nano-suspension dry powder. The Herpetetrone nanosuspension or the Herpetetrone nanosuspension dry powder dissolves more than 90% within 2 hours; it has a significant inhibitory effect on the proliferation of HSC-T6 liver fibroblasts. The application is in the preparation of medicines for treating liver diseases. The invention has the following advantages: the dissolution rate in vitro is obviously improved, the oral bioavailability in vivo is obviously improved, and the inhibitory effect on HSC-T6 cells is enhanced simultaneously.
Owner:AIR FORCE MEDICAL CENT PLA
Application of sanguinarine in inhibiting growth of streptococcus pneumonia
PendingCN111166749AGrowth inhibitionDefinite inhibitory effectAntibacterial agentsOrganic active ingredientsMicrobiologySanguinarine
The invention discloses an application of sanguinarine in inhibiting the growth of streptococcus pneumonia, according to the fact that the sanguinarine has a good in-vitro killing effect on streptococcus pneumonia, the sanguinarine can inhibit the growth of streptococcus pneumonia, the minimum bactericidal concentration is 31.2 mu g / mL, and the minimum inhibitory concentration is 15.6 mu g / mL. Thesanguinarine provided by the invention has an inhibition effect on pneumonia streptococcus, and has a wide application value in the fields of medicines and the like.
Owner:SHAANXI UNIV OF SCI & TECH
Fusion protein of tumour new-born blood vessel-specific bonding polypeptide and recombinant human Tum-5, and its preparation method
InactiveCN100390202CAntitumor effect is obviousPrevent proliferationRecombinant DNA-technologyFermentationTumour tissueEscherichia coli
The invention discloses a method for preparing for tumour formingblood vessel peculiarity binding polypeptide and the admixture protein of human-5. The tumour formingblood vessel peculiarity binding polypeptid-CNGRCVSGCAGRC can separately combine with the tumour formingblood vessel endothelium cell surface high effect expressed aminopeptidase N (CD13). It establishes tumour formingblood vessel peculiarity binding polypeptide and the admixture protein of human-5 and obtains the high effect express in bacillus coli. It also discloses a method for preparing for human Tum-5. The Tum-5 is formed by the 54-132 bits amino acid near the N end of the Tumstatin, which is the function structure area of the Tumstatin anti-vascularization.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Application of polyphyllin in preparation of anti-candida albicans fluconazole drug-resistant strain product and anti-dermatophyte product
PendingCN114432326ADelay drug resistanceLess irritatingOrganic active ingredientsAntimycoticsBiotechnologyAntifungal drug
The invention relates to the technical field of microbial antibiosis, and provides application of polyphyllin in preparation of a product for resisting a candida albicans fluconazole drug-resistant strain and a product for resisting dermatophyte. The polyphyllin has a definite inhibition effect on a candida albicans fluconazole drug-resistant strain, epidermophyton flocculent, microsporum gypsum and trichophyton rubrum, is steroidal saponin, and is greatly different from the currently common azole antifungal drugs such as ketoconazole, fluconazole, itraconazole and the like in structure. The mechanism of the polyphyllin for resisting a candida albicans fluconazole-resistant strain, epidermophyton flocculent, microsporum gypsum or trichophyton rubrum is different from that of azole antifungal drugs, and the polyphyllin is added into the antibacterial product, so that the common antifungal drug-resistant bacteria can be inhibited, the drug resistance and irritation of the preparation are reduced, and the safety of the preparation is improved.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Palmatine hydrochloride-aspirin supramolecular compound
ActiveCN114478517AThe preparation method is green and efficientClear crystal structureAntibacterial agentsOrganic active ingredientsStructural unitPalmatine hydrochloride
The invention discloses a palmatine hydrochloride-aspirin supramolecular compound as well as a preparation method and application thereof, and belongs to the technical field of medicine crystallization. The structural unit of the pharmaceutical co-crystal comprises palmatine hydrochloride molecules, aspirin molecules and water molecules, the molar ratio of the palmatine hydrochloride molecules to the aspirin molecules to the water molecules is 1: 1: 1, and the molecular formula of the pharmaceutical co-crystal is [C21H22ClNO3]. [C9H8O4]. H2O. The palmatine hydrochloride-aspirin supramolecular compound is prepared by mixing a palmatine hydrochloride hydrate and aspirin in a solvent according to a molar ratio of 1: 1 and carrying out spray drying, evaporation or suspension stirring and other processes, the preparation method is green and efficient, and the supramolecular compound is high in light stability, wet stability and thermal stability and weak in hygroscopicity, and can be used for preparing the palmatine hydrochloride-aspirin supramolecular compound. The compound has good human colorectal cancer cell inhibition activity, and can be used as an active component for preparing a pharmaceutical composition or a health care product for treating or preventing colorectal cancer.
Owner:MINJIANG UNIV +1
Application of luteolin in inhibiting the growth of multi-drug-resistant Providencia reinhardtii
ActiveCN110934859BGrowth inhibitionDefinite inhibitory effectAntibacterial agentsOrganic active ingredientsProvidencia sp.Drug resistance
The invention discloses the application of luteolin in inhibiting the growth of multi-drug-resistant Providencia rettgeri. According to the fact that luteolin has a good in vitro killing effect on multi-drug-resistant Providencia rettgeri, it can inhibit multiple The growth of drug-resistant Providencia rettgeri, and the minimum bactericidal concentration is 30 ~ 250 μg / mL, the minimum inhibitory concentration is 15 ~ 125 μg / mL, the present invention proposes that luteolin is effective against multidrug-resistant Providencia rettgeri The inhibitory effect of S. spp. has wide application value in medicine and other fields.
Owner:SHAANXI UNIV OF SCI & TECH
Herpetetrone nanosuspension and dry powder thereof, and preparation methods and applications of herpetetrone nanosuspension and dry powder
ActiveCN111374944ADefinite inhibitory effectEnhanced inhibitory effectPowder deliveryDigestive systemPharmaceutical drugBioavailability
The invention provides a Herpetetrone nanosuspension and dry powder thereof, and preparation methods and applications of the herpetetrone nanosuspension and the dry powder and belongs to the technicalfield of traditional Chinese medicinal oral drugs. The Herpetetrone nanosuspension is prepared through an ultrasonic precipitation method. The preparation method of the dry powder of the suspension comprises preparation of the Herpetetrone nanosuspension, and preparation of the dry powder of the Herpetetrone nanosuspension. The dissolvability of the Herpetetrone nanosuspension or the dry powder of the Herpetetrone nanosuspension within 2 h is up to above 90%, and the Herpetetrone nanosuspension or the dry powder of the Herpetetrone nanosuspension has a significant inhibition effect on HSC-T6hepatocyte proliferation. The application is an application in preparation of drugs for treating liver diseases. The Herpetetrone nanosuspension has the advantages that the in-vitro dissolubility is obviously improved, the oral bioavailability in vivo is obviously improved, and meanwhile, the inhibition effect on HSC-T6 cells is enhanced.
Owner:AIR FORCE MEDICAL CENT PLA
Application of chelerythrine in inhibiting growth of streptococcus pneumonia
PendingCN111202735AGrowth inhibitionDefinite inhibitory effectAntibacterial agentsOrganic active ingredientsChelirubineMicrobiology
The invention discloses an application of chelerythrine in inhibiting the growth of streptococcus pneumonia. According to the fact that the chelerythrine has good in-vitro bactericidal effect on the streptococcus pneumonia, the chelerythrine can inhibit the growth of the streptococcus pneumonia, and has a minimum bactericidal concentration of 31.2 [mu]g / mL and a minimum bacteriostatic concentration of 15.6 [mu]g / mL. The invention provides the inhibition effect of the chelerythrine on the streptococcus pneumonia; and the chelerythrine has wide application value in the fields of medicines and the like.
Owner:SHAANXI UNIV OF SCI & TECH
Method and application of preparing amides and esters by using marine bacillus amyloliquefaciens
ActiveCN107418984BDefinite inhibitory effectBiocideMicroorganism based processesBiotechnologySephadex
A method for preparing 13-docosenamide by fermenting a marine bacillus amyloliquefaciens BMF01 bacterial strain comprises the following steps: fermentation of the BMF01 bacterial strain and preparation of fermentation broth thereof, acid precipitation of the fermented broth of the BMF01 bacterial strain and methanol extraction, silica gel column chromatography of BMF01 bacterial strain fermentation broth methanol extract, Sephadex LH-20 column chromatography, then the absorption peak of MD-4 components appear at 11.5 min, and is identified to be a structure of the compound 13-docosenamide. The invention also relates to a method for preparing ester compounds from marine bacillus amyloliquefaciens BMF01. The method of the invention produces the 13-docosenamide and ester compounds having the application of inhibiting root rot of wheat. For the first time, five kinds of compounds with bacteriostatic action are prepared on the basis of BMF01 strain. The method has the advantages of simple method and high operability.
Owner:HUAIHAI INST OF TECH
Antibacterial dentin adhesive and preparation method thereof
PendingCN114569472ADefinite inhibitory effectParticle size controllableImpression capsDentistry preparationsTooth fillingNanoparti cles
The invention discloses an antibacterial dentin adhesive and a preparation method thereof. Relates to the technical field of tooth filling and repairing. Comprising Zn-N-TiO2NPs (Zn-N-TiO2Nanoparticles, Zn-N-TiO2 nanoparticles), the doping concentration of titanium dioxide in the Zn-N-TiO2NPs is as follows: the doping concentration of zinc is 2.8%-3.2%, and the doping concentration of nitrogen is 2.8%-3.2%, and the invention also provides a preparation method. Zinc nitrate hexahydrate and ammonia water are adopted as sources of zinc and nitrogen respectively, titanium dioxide is co-doped through a sol-hydrothermal method, novel Zn and N co-doped titanium dioxide nanoparticles are prepared, under the condition that Zn-N-TiO2NPs is optically excited by a dental LED, the inhibition effect of the nanoparticles on streptococcus mutans is determined, and the application prospect is broad. The invention aims to provide a theoretical basis for the application of Zn-N-TiO2NPs in the field of caries prevention. Meanwhile, the prepared particles are controllable in particle size and uniform in size.
Owner:JILIN UNIV
Medicine for inhibiting growth of enterococcus faecium
InactiveCN111419847AGrowth inhibitionDefinite inhibitory effectAntibacterial agentsOrganic active ingredientsBiotechnologyResistant bacteria
The invention discloses a medicine for inhibiting the growth of enterococcus faecium. The medicine comprises sanguinarine. According to the invention, a potential drug-resistant bacteria inhibitor isexcavated from an existing medicinal plant resource library. Based on the research of the action of the sanguinarine on enterococcus faecium, the invention discovers that the non-antibiotic compound sanguinarine can effectively inhibit the growth of the enterococcus faecium, provides a new thought and source for the research, development and application of an enterococcus faecium inhibitor, and has wide application value in the fields of medicines and the like. According to the invention, the inhibition effect of the sanguinarine on the enterococcus faecium is determined, and the sanguinarineis used as an antibiotic substitute, can effectively relieve or solve the problems of drug resistance and infection of the enterococcus faecium, and reduces the mortality.
Owner:济宁市第一人民医院
Application of protoopioid alkaloids in the preparation of medicines for inhibiting p-gp
ActiveCN104248635BDefinite inhibitory effectIncrease lethalityOrganic active ingredientsAntineoplastic agentsAlkaloidRacemic mixture
The present invention provides proto-opioid alkaloids and pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or racemic mixture salts, polymorphs, optical isomers, racemates, and Application of Corydalis Corydalis and its extracts containing proto-opioid alkaloids, Xia Wu and its extracts, Boluohui and its extracts in the preparation of drugs for inhibiting P-gp function. The present invention also provides proto-opioid alkaloids and pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or racemic mixture salts, polymorphs, optical isomers, and racemates, And the application of Corydalis Corydalis and its extracts containing original opioid alkaloids, Xia Wu and its extracts, Boluohui and its extracts in the preparation of drugs for adjuvant tumor treatment, the adjuvant tumor treatment refers to the reversal of the combination of P ‑Gp high expression related tumor multidrug resistance, synergistic antitumor drugs.
Owner:TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
An antibacterial and antiviral preparation mainly composed of kidney bean lectin
ActiveCN108404111BDefinite inhibitory effectConsistent qualityAntibacterial agentsAntimycoticsCelluloseChloraPrep
Owner:YUNNAN KANGZHOU BIOLOGICAL SCI & TECH
Application of chelerythrine in inhibiting growth of multi-drug resistant providencia rettgeri
ActiveCN111000845ADefinite inhibitory effectAlleviate or resolve drug resistanceAntibacterial agentsOrganic active ingredientsMolecular biologyProvidencia rettgeri
The invention discloses application of chelerythrine in inhibiting the growth of multi-drug resistant providencia rettgeri. Chelerythrine has a good in-vitro killing effect, can inhibit the growth ofmulti-drug resistant providencia rettgeri, also a minimum bactericidal concentration is 20-250microg / mL, and a minimal inhibitory concentration is 10-125microg / mL. The invention puts forward the inhibition effect of chelerythrine on the multi-drug resistant providencia rettgeri, and has wide application value in medicine and other fields.
Owner:SHAANXI UNIV OF SCI & TECH
Use of Asterias rollestoni Bell extract in preparation of antitumor drug
ActiveCN103230417BModerate antitumor activityDefinite inhibitory effectOrganic active ingredientsDigestive systemN-ButanolSolvent
The invention relates to the field of preparation of antitumor drugs and especially relates to a use of Asterias rollestoni Bell extract in preparation of an antitumor drug. The Asterias rollestoni Bell extract is Asterias rollestoni Bell alcohol extract extracted from Asterias rollestoni Bell by a solvent. The solvent is a methanol aqueous solution or an ethanol aqueous solution or a mixed solution of methanol and ethanol. The Asterias rollestoni Bell extract also can be ethyl acetate extract or n-butanol extract of the Asterias rollestoni Bell alcohol extract. An experiment proves that the Asterias rollestoni Bell extract has moderate antitumor activity, and can obviously inhibit mice H22 solid tumor and mice S180 solid tumor, and especially, the ethyl acetate extract of the Asterias rollestoni Bell alcohol extract has obvious inhibition effects. Therefore, the Asterias rollestoni Bell extract can be used for treating cancers and especially for liver cancer.
Owner:SOUTH CHINA SEA INST OF OCEANOLOGY - CHINESE ACAD OF SCI
Application of sanguinarine in inhibiting growth of multi-drug-resistant serratia marcescens
ActiveCN110934871AGrowth inhibitionDefinite inhibitory effectAntibacterial agentsOrganic active ingredientsSerratia speciesSanguinarine
The invention discloses an application of sanguinarine in inhibiting growth of multi-drug resistant serratia marcescens. According to the invention, sanguinarine has a good in vitro killing effect onmulti-drug resistant serratia marcescens; the sanguinarine can inhibit the growth of the multi-drug-resistant serratia marcescens, the minimum inhibitory concentration is 0.025-0.2 mg / mL, and the minimum bactericidal concentration is 0.05-0.4 mg / mL. The invention provides an inhibition effect of the sanguinarine on the multi-drug-resistant serratia marcescens, and the sanguinarine has wide application value in the fields of medicines and the like.
Owner:SHAANXI UNIV OF SCI & TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com